![Dodzie Sogah](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Dodzie Sogah
Director/Board Member at Cystic Fibrosis Foundation
Dodzie Sogah active positions
Companies | Position | Start | End |
---|---|---|---|
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 31/05/2022 | - |
Cystic Fibrosis Foundation
![]() Cystic Fibrosis Foundation Medical/Nursing ServicesHealth Services Cystic Fibrosis Foundation is a donor-supported non-profit organization which focuses in the search for a cure for cystic fibrosis. The foundation funds cystic fibrosis research. It also supports and accredits a national care center network recognized by the National Institutes f Health as a model of care for a chronic disease. The company was founded in 1955 and is headquartered in Bethesda, MD. | Director/Board Member | 08/08/2023 | - |
Career history of Dodzie Sogah
Former positions of Dodzie Sogah
Companies | Position | Start | End |
---|---|---|---|
SCHOLAR ROCK HOLDING CORPORATION | Corporate Officer/Principal | 29/02/2016 | 28/02/2021 |
Septerna, Inc.
![]() Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Chief Operating Officer | 31/03/2021 | - |
VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - | - |
Training of Dodzie Sogah
Harvard University | Graduate Degree |
Harvard Medical School | Doctorate Degree |
Statistics
International
United States | 8 |
Operational
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 3 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
Private companies | 3 |
---|---|
Cystic Fibrosis Foundation
![]() Cystic Fibrosis Foundation Medical/Nursing ServicesHealth Services Cystic Fibrosis Foundation is a donor-supported non-profit organization which focuses in the search for a cure for cystic fibrosis. The foundation funds cystic fibrosis research. It also supports and accredits a national care center network recognized by the National Institutes f Health as a model of care for a chronic disease. The company was founded in 1955 and is headquartered in Bethesda, MD. | Health Services |
Septerna, Inc.
![]() Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Health Technology |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
- Stock Market
- Insiders
- Dodzie Sogah
- Experience